secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMARIN CORP PLCUK (AMRN)
CIK:        0000897448
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0000950170-23-057121
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amarin Q3 2023: Revenue $66M (-27% YoY), net loss $19.3M; cash flow +$8M
------------------------------------------------------------------------

- Total net revenue $66.1M, down 27% vs Q3 2022; net loss $19.3M vs $5.1M loss a year ago; diluted EPS loss $0.05.
- U.S. net product revenue $62.4M (-3% sequentially); maintained ~57% IPE market share despite generic competition.
- European revenue $0.8M; early launches in UK, Spain, Netherlands with progress under new leadership.
- Generated $8M positive cash flow in quarter; cash and investments $321M; on track for $40M annual savings from July restructuring.
- Partner Edding launched VASCEPA in China for severe hypertriglyceridemia; submitted CVRR indication filing to NMPA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/897448/000095017023057121/0000950170-23-057121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/897448/000095017023057121/amrn-20231101.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-057121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer